TITLE

Olmesartan, Amlodipine, Hydrochlorothiazide Tablets (Tribenzor)

AUTHOR(S)
Elliott, William T.; Chan, James
PUB. DATE
September 2010
SOURCE
Internal Medicine Alert;9/15/2010, Vol. 32 Issue 17, p113
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article focuses on the use of the single-pill combination of olmesartan (OLM), amlodipine (AML), and hydrochlorothiazide (HCTZ), marketed as Tribenzor by Daiichi Sankyo Inc., on the treatment of hypertension.
ACCESSION #
54442499

 

Related Articles

  • Guancydine: A New Antihypertensive Agent. Clark, Dwight W.; Goldberg, Leon I. // Annals of Internal Medicine;Apr72, Vol. 76 Issue 4, p579 

    Discusses a study which evaluated the efficacy and acceptability of guancydine as part of the therapeutic program for patients with hypertension. Dosage regimens administered to the study population; Clinical presentation of the patients; Adverse effects of guancydine.

  • Hypertension Drug Debuts.  // Chain Drug Review;2/27/2012, Vol. 34 Issue 4, p44 

    The article offers information on Edarbyclor, an antihypertensive drug for the treatment of hypertension in adults of the U.S.

  • Resistant hypertension: What to do after trying `the usual'. Kaplan, Norman M. // Geriatrics;May95, Vol. 50 Issue 5, p24 

    Discusses the management of resistant hypertension. Incidence of resistant hypertension; Factors that cause poor response to antihypertensive drug therapy; Physiologic causes of resistant hypertension; Ways to improve drug compliance.

  • Treating hypertension: the evidence from clinical trials. Simon, Joel A. // BMJ: British Medical Journal (International Edition);8/24/96, Vol. 313 Issue 7055, p437 

    Editorial. Discusses the hypertensive treatment modalities. Evolving guidelines in treating hypertension; Analyses of the clinical trials of antihypertensive drugs; Parameters of drug effectiveness.

  • Candesartan Cilexetil: An Update of its Use in Essential Hypertension. Easthope, S.E.; Jarvis, B. // Drugs;2002, Vol. 62 Issue 8, p1253 

    Candesartan cilexetil is converted to the angiotensin II receptor antagonist candesartan during absorption from the gastrointestinal tract. The selective and competitive binding of candesartan to the angiotensin II type 1 (AT) receptor prevents binding of angiotensin II, a key mediator in the...

  • Continuing Education Case Study Quiz.  // Hospital Pharmacy;Aug2007, Vol. 42 Issue 8, p747 

    A quiz about the use of aliskiren in the treatment of hypertension is presented.

  • Additional Non-Pharmacological Methods of Treatment in Patients on Antihypertensive Drugs: Results of Previous Medication, Laboratory test and Life Quality.  // JAMA: Journal of the American Medical Association;1/12/90, Vol. 263 Issue 2, p296 

    Presents an abstract of the study 'Addition of Non-Pharmacological Methods of Treatment in Patients on Antihypertensive Drugs: Results of Previous Medication, Laboratory Tests and Life Quality,' published in an issue of the 'Journal of Internal Medicine.'

  • Hypertension control still suboptimal in the US.  // PharmacoEconomics & Outcomes News;Sep2015, Vol. 736 Issue 1, p15 

    The article discusses research on the rates of hypertension control and antihypertensive prescription in the U.S., conducted by A. Gu et al, published in the August 21, 2015 issue of the "American Journal of Medicine."

  • Hypertension 1973: Treatment--Why and How. Frohlich, Edward D. // Annals of Internal Medicine;May73, Vol. 78 Issue 5, p717 

    Discusses the controversy on the merits of long-term antihypertensive therapy for hypertension. Cases for antihypertensive therapy; Evaluation and treatment of hypertension; Problems with hypertension in the U.S.

  • Health outcomes associated with antihypertensive therapies used as first-line agents. Psaty, Bruce M.; Smith, Nicholas L. // JAMA: Journal of the American Medical Association;3/5/97, Vol. 277 Issue 9, p739 

    Presents a study, the objective of which is to review the scientific evidence concerning the safety and efficacy of various antihypertensive therapies used as first-line agents and evaluated in terms of major disease end points. Data sources; Data selection; Data synthesis; Conclusion.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics